127 related articles for article (PubMed ID: 6394890)
1. Prolonged infusion of prostacyclin in patients with advanced stages of peripheral vascular disease: a placebo-controlled cross-over study.
Hossmann V; Auel H; Rücker W; Schrör K
Klin Wochenschr; 1984 Dec; 62(23):1108-14. PubMed ID: 6394890
[TBL] [Abstract][Full Text] [Related]
2. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease.
Cronenwett JL; Zelenock GB; Whitehouse WM; Lindenauer SM; Graham LM; Stanley JC
Surgery; 1986 Aug; 100(2):369-75. PubMed ID: 3526609
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris.
Théroux P; Latour JG; Diodati J; Léger-Gauthier C; Morissette D; Bosch X; de Lara J; Waters D
Am J Cardiol; 1990 May; 65(16):1084-9. PubMed ID: 2109927
[TBL] [Abstract][Full Text] [Related]
4. The effect of clinical prostacyclin infusions in advanced arterial disease on platelet function and plasma 6-keto PGF1 alpha levels.
Machin SJ; Chamone DA; Defreyn G; Vermylen J
Br J Haematol; 1981 Mar; 47(3):413-22. PubMed ID: 7006673
[TBL] [Abstract][Full Text] [Related]
5. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
Maksimović ZV
Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
[TBL] [Abstract][Full Text] [Related]
6. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers.
Reele SB; Miller OV; Spillers C; Gorman RR
Prostaglandins; 1983 Aug; 26(2):287-302. PubMed ID: 6316420
[TBL] [Abstract][Full Text] [Related]
7. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
[TBL] [Abstract][Full Text] [Related]
8. Platelet hyperactivity in acute myocardial infarction in man--effects of prostacyclin.
Mueller HS; Rao PS; Greenberg MA; Buttrick PM; Sussman II; Levite HA; Grose RM; Perez-Davila V; Strain JE; Spaet TH
Herz; 1986 Apr; 11(2):116-26. PubMed ID: 2939012
[TBL] [Abstract][Full Text] [Related]
9. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
Manrique RV; Manrique V
Angiology; 1987 Feb; 38(2 Pt 1):101-8. PubMed ID: 3030162
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.
Darius H; Hossmann V; Schrör K
Klin Wochenschr; 1986 Jun; 64(12):545-51. PubMed ID: 2426514
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic effects of intravenous prostacyclin in stable angina pectoris.
Firth BG; Winniford MD; Campbell WB; Hillis LD
Am J Cardiol; 1983 Sep; 52(5):439-43. PubMed ID: 6351580
[TBL] [Abstract][Full Text] [Related]
12. Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization.
DiSesa VJ; Huval W; Lelcuk S; Jonas R; Maddi R; Lee-Son S; Shemin RJ; Collins JJ; Hechtman HB; Cohn LH
Ann Thorac Surg; 1984 Nov; 38(5):514-9. PubMed ID: 6388516
[TBL] [Abstract][Full Text] [Related]
13. Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response.
Skrinska VA; Lucas FV; Chisolm GM; Hesse BL
J Lab Clin Med; 1986 Mar; 107(3):187-93. PubMed ID: 3512745
[TBL] [Abstract][Full Text] [Related]
14. A double blind study of prostacyclin in cardiopulmonary bypass surgery.
Walker ID; Davidson JF; Faichney A; Wheatley DJ; Davidson KG
Br J Haematol; 1981 Nov; 49(3):415-23. PubMed ID: 6457624
[TBL] [Abstract][Full Text] [Related]
15. Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man.
Sinzinger H; Fitscha P; Kaliman J; Silberbauer K; O'Grady J
Br J Clin Pharmacol; 1987 Nov; 24(5):607-13. PubMed ID: 3325091
[TBL] [Abstract][Full Text] [Related]
16. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
Belch JJ; Newman P; Drury JK; McKenzie F; Capell H; Leiberman P; Forbes CD; Prentice CR
Lancet; 1983 Feb; 1(8320):313-5. PubMed ID: 6130329
[TBL] [Abstract][Full Text] [Related]
17. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin.
Mueller HS; Rao PS; Greenberg MA; Buttrick PM; Sussman II; Levite HA; Grose RM; Perez-Davila V; Strain JE; Spaet TH
Circulation; 1985 Dec; 72(6):1336-45. PubMed ID: 2933181
[TBL] [Abstract][Full Text] [Related]
18. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
Fletcher JR; Ramwell PW
Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
[TBL] [Abstract][Full Text] [Related]
19. Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease.
Buchanan MR; Butt RW; Turpie AG
Am Heart J; 1987 May; 113(5):1133-7. PubMed ID: 2953219
[TBL] [Abstract][Full Text] [Related]
20. A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease.
Virgolini I; Fitscha P; Linet OI; O'Grady J; Sinzinger H
Prostaglandins; 1990 Jun; 39(6):657-64. PubMed ID: 2115186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
